The Statistical Unit (SU) for RTOG is headed by Dr. Thomas Pajak. When all treatment studies were made the responsibility of the six disease committees, the RTOG SU was accordingly restructured so that a senior statistician is assigned to each disease committee and the CCOP program. The senior statistician collaborates with the committee chair and the specific study chairs in developing and implementing suitable study designs and appropriate randomization plans. The statisticians interact with the study chair, headquarters research associate, and RT assurance staff in refining the protocol and in developing the data collection forms, quality control procedures for treatment delivery, and the computerized audit check for protocol data. The statisticians prepare interim analyses for every open RTOG study for the semi-annual meeting. The statisticians are located on the same floor and in the same contiguous space as the protocol, randomization, and data management staff that are included as part of the RTOG headquarters. The senior statisticians meet weekly to review activities and establish deadlines for the preparation of the semi-annual statistical reports and other related projects. This interaction enhances the communication among them and meets the need for coordination of study design, monitoring, and the analysis. The senior statisticians meet with the Group Chair monthly to review the SU's activities and to identify problems relating to RTOG studies or other activities. There is a weekly meeting of the five section heads, which include Dr. Pajak representing the SU and the four heads from the headquarters: administration, protocol administration, data management, and radiation quality assurance.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA032115-17
Application #
2633748
Study Section
Subcommittee G - Education (NCI)
Program Officer
Kaplan, Richard S
Project Start
1982-04-15
Project End
2001-12-31
Budget Start
1998-01-01
Budget End
1998-12-31
Support Year
17
Fiscal Year
1998
Total Cost
Indirect Cost
Name
American College of Radiology
Department
Type
DUNS #
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Li, Donghui; Moughan, Jennifer; Crane, Christopher et al. (2016) RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncology Group 9704. Int J Radiat Oncol Biol Phys 94:554-60
Hamstra, Daniel A; Bae, Kyounghwa; Hanks, Gerald et al. (2015) Impact of biochemical failure classification on clinical outcome: a secondary analysis of Radiation Therapy Oncology Group 9202 and 9413. Cancer 121:844-52
Ben-Josef, Edgar; George, Asha; Regine, William F et al. (2015) Glycogen Synthase Kinase 3 Beta Predicts Survival in Resected Adenocarcinoma of the Pancreas. Clin Cancer Res 21:5612-8
Xiao, Canhua; Hanlon, Alexandra; Zhang, Qiang et al. (2014) Risk factors for clinician-reported symptom clusters in patients with advanced head and neck cancer in a phase 3 randomized clinical trial: RTOG 0129. Cancer 120:848-54
Cairncross, J Gregory; Wang, Meihua; Jenkins, Robert B et al. (2014) Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol 32:783-90
Komaki, Ritsuko; Paulus, Rebecca; Blumenschein Jr, George R et al. (2014) EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324. Radiother Oncol 112:30-6
Hsu, I-Chow; Hunt, Daniel; Straube, William et al. (2014) Dosimetric analysis of radiation therapy oncology group 0321: the importance of urethral dose. Pract Radiat Oncol 4:27-34
Xiao, Canhua; Hanlon, Alexandra; Zhang, Qiang et al. (2013) Symptom clusters in patients with head and neck cancer receiving concurrent chemoradiotherapy. Oral Oncol 49:360-6
Cairncross, Gregory; Wang, Meihua; Shaw, Edward et al. (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337-43
Lawrence, Yaacov Richard; Paulus, Rebecca; Langer, Corey et al. (2013) The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801. Lung Cancer 80:298-305

Showing the most recent 10 out of 274 publications